Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：20

作者：

Takimoto, Takayuki ^{[1
]}

Nakabori, Tasuku ^{[1
]}

Osa, Akio ^{[1
]}

Morita, Satomu ^{[1
]}

Terada, Haruko ^{[1
]}

Oseto, Susumu ^{[1
]}

Iwazawa, Takashi ^{[2
]}

Abe, Kinya ^{[1
]}

机构：

[1] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan

[2] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka 5608565, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 17卷 / 04期

关键词：

Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; beta(2)-Microglobulin; RENAL-FUNCTION; CISPLATIN; CHEMOTHERAPY; PLATINUM; TAXOTERE;

D O I：

10.1007/s10147-011-0304-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

引用

页码：395 / 398

页数：4

共 50 条

[31] Non-small-cell lung cancer
不详
NATURE REVIEWS DISEASE PRIMERS, 2024, 10 (01):
[32] Non-small-cell lung cancer
Nature Reviews Disease Primers, 1 (1)
[33] Non-small-cell lung cancer
Goldstraw, Peter
Ball, David
Jett, James R.
Le Chevalier, Thierry
Lim, Eric
Nicholson, Andrew G.
Shepherd, Frances A.
LANCET, 2011, 378 (9804): : 1727 - 1740
[34] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Brahmer, Julie
Reckamp, Karen L.
Baas, Paul
Crino, Lucio
Eberhardt, Wilfried E. E.
Poddubskaya, Elena
Antonia, Scott
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin
Aren Frontera, Osvaldo
Havel, Libor
Steins, Martin
Garassino, Marina C.
Aerts, Joachim G.
Domine, Manuel
Paz-Ares, Luis
Reck, Martin
Baudelet, Christine
Harbison, Christopher T.
Lestini, Brian
Spigel, David R.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02): : 123 - 135
[35] Exploration of lung mycobiome in the patients with non-small-cell lung cancer
Yiming Zhao
Junqi Yi
Juanjuan Xiang
Wei Jia
Anqi Chen
Liyu Chen
Leliang Zheng
Wen Zhou
Minghua Wu
Zheng Yu
Jingqun Tang
BMC Microbiology, 23
[36] Exploration of lung mycobiome in the patients with non-small-cell lung cancer
Zhao, Yiming
Yi, Junqi
Xiang, Juanjuan
Jia, Wei
Chen, Anqi
Chen, Liyu
Zheng, Leliang
Zhou, Wen
Wu, Minghua
Yu, Zheng
Tang, Jingqun
BMC MICROBIOLOGY, 2023, 23 (01)
[37] Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer
Xu, Liqin
Qin, Yan
Huang, Jianfei
Qin, Jing
Gu, Jun
Zhu, Huijun
Liu, Hong
Cai, Yifeng
Wu, Xinhua
Feng, Jian
ANTI-CANCER DRUGS, 2013, 24 (04) : 406 - 414
[38] Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer
Herse, B
Dalichau, H
Wörmann, B
Hemmerlein, B
Schmidberger, H
Hess, CF
Hannemann, P
Criée, CP
Hiddemann, W
Griesinger, F
THORACIC AND CARDIOVASCULAR SURGEON, 1998, 46 (05): : 298 - 302
[39] Docetaxel (Taxotere®) in the neo-adjuvant setting in non-small-cell lung cancer
Mattson, K
ANNALS OF ONCOLOGY, 1999, 10 : 69 - 72
[40] Development of psoriasis during docetaxel therapy in a patient with non-small-cell lung cancer
Watabe, Daisuke
Amano, Hiroo
JOURNAL OF DERMATOLOGY, 2020, 47 (12): : E427 - E428

← 1 2 3 4 5 →